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A B S T R A C T 
 
 
Spending on medical care is a large and growing component of GDP.  There are well-
known measurement problems that are estimated to overstate inflation and understate real 
growth for this sector by as much as 1-1/2 percentage points per year.  Because of its 
size, this would translate into an overstatement of inflation for the overall economy of 
about ¼ percentage point with an equal understatement in real GDP growth.  In this 
paper, we use data from the Medical Expenditure Panel Survey to obtain new, more 
comprehensive estimates for this bias and to explore a possible adjustment to existing 
official price indexes.  The MEPS data show an upward bias to price growth in this sector 
of 1 percentage point, which translates into an overstatement of overall inflation of .2 
percentage point and an understatement of GDP growth of the same amount.  We also 
find that an adjustment recently used in Bradley et al provides a useful approximation to 
the indexes advocated by health economists.   
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  1I.  INTRODUCTION 
   
The historical rise in health care expenditures is a major national concern. In 
1960, the ratio of national health care expenditures to GDP was 5.2%. Almost fifty years 
later, in 2008, this ratio had increased more than threefold to 16.2% and is expected to 
continue to increase to more than 19% by 2019 (Hartman et al 2010).   
In light of this growing presence in the economy, it is essential that statistical 
agencies be able to accurately measure what part of this growth is inflationary, and what 
part is an increase in output. The generation of biased medical price indexes would 
generate a biased decomposition of health care expenditure growth into inflation and 
output growth, and this could misinform health care policy discussions.    
This study focuses on this important issue of constructing of health care price 
indexes that are used to measure health care inflation. There is wide empirical evidence 
that the traditional methods used by the Bureau of Labor Statistics (BLS) to compute 
medical price indexes lead to upward bias.  This issue was first addressed over forty years 
ago by Scitovsky (1967) when she computed alternative medical indexes for a single 
clinic in Palo Alto. She found that a price index for the treatment of conditions generated 
different results than a price index for individual medical services.  After her study, this 
issue remained dormant for over twenty years, and no study by another author tried to 
apply her methods used in a single clinic to a national setting. However, during the past 
twenty years, there have been studies such as Shapiro and Wilcox (1996), Berndt et al. 
(1996, 1998, 2000), and Cutler et al. 1998 that focus on deriving a price index for a single 
disease rather than for a service.  All these studies conclude that the traditional BLS 
method overstated the true price indexes for the specific diseases covered in their studies. 
These studies prompted the Committee on National Statistics to call on statistical 
agencies to report national expenditures, price indexes, and output by disease rather than 
by medical service.
2  
Building on the more recent studies that focused on one disease, newer studies 
have attempted to find results to an index that covered all diseases. Song et. al 2009 find 
that indeed traditional methods did lead to upward bias. This study is based on forty 
                                                           
2 See National Research Council (2010), Mackie (2009), and Schultze C. and Mackie C., (2002). 
  2randomly selected diseases for patients in three cities and used a non representative 
claims data base for only privately administered plans. Aizcorbe and Nestoriak 2010 and 
Dunn et al 2010 use a claims data that are more comprehensive for geographically areas 
and medical conditions. They also find bias in existing BLS methods. Bradley et. al 2010 
combine the Medical Expenditure Panel Survey (MEPS) with the BLS databases to 
explore possible adjustments to the BLS price indexes that account for this bias and 
found large numerical differences in the adjusted vs unadjusted price indexes.
3 
This study continues to compare the traditional BLS method to the disease based 
approach. Unlike previous studies, this study uses only MEPS data to determine i) the 
effect on published health inflation data if the price index were to change from a service 
price index (SPI) to an alternative index that accounts for changes in service mix when 
treating a disease (hereafter the “medical care indexes (MCE)), ii) the difference between 
using the adjustment method used in Bradley et al and the MCE indexes, iii) and how 
using different disease classifications and comorbidity methods impact the MCE indexes. 
This study finds that traditional price index methods generate an annual 1 
percentage point upward bias on the medical price indexes that are computed with 
traditional methods.  This translates into an overall .2 percentage point overstatement for 
overall inflation with an attendant understatement of the same amount to GDP growth.  In 
addition to these distortions to macroeconomic statistics, the traditional indexes and the 
MCE indexes give us different reasons for the threefold rise of the ratio of medical 
spending to GDP from 1960 to 2008.  As such, existing measures do not properly 
characterize growth in health care markets.  This issue and these results are also critically 
important for our understanding of health care markets. 
This paper is organized as follows: Section II describes the price indexes and the 
three methods for allocating spending by disease; Section III details the data and 
                                                           
3 The reason that price imputation is evaluated is that BLS publishes indexes on a monthly basis and MEPS 
data is only available annually. Therefore, the monthly prices used to generate a monthly index can come 
from two sources. The first source is a medical insurance claims database. But, these databases are 
expensive and BLS would take on delivery risk if the vendor could not supply this data before the index 
publication date. The second source, price imputation, using existing price indexes would not require any 
additional budgetary outlays.  BLS is working towards publishing experimental indexes that use this 
adjustment strategy (Horrigan 2010).   
 
  3definitions; Section IV presents the study’s findings and price indexes produced by each 




We explore the potential bias in official price indexes by using the MEPS data to 
construct a price index of the same structure as the official price indexes provided by 
BLS and compare it to the type of index preferred by health economists.  Both of these 
indexes have the problem that they do not account for changes in outcomes associated 
with care.  However, it is widely held that the latter provide a better measure of price 
change than the traditional service price (SPI) indexes and that is our focus in this paper.
4   
The conventional price indexes are treatment-based, detailing spending according 
to specific treatments and procedures, such as a doctor’s office visit or a particular drug.  
They reflect what is happening to the provider prices of a fixed basket of goods and 
services.  By design, these indexes will only capture the effect of increased provider 
prices, not shifts to lower-cost services.  Following Cutler et al. (1998), we call these 
fixed-basket indexes service price indexes, or SPIs; these SPIs are the official Laspeyres 
indexes produced by the Bureau of Labor Statistics (BLS).  They answer the question 
“What would expenditures be if patients received the same services today as they did in 
the past?”   
Health economists have long advocated pricing “episodes of care” or the 
“treatment of a condition” rather than the specific medical services provided (Scitovsky 
1964).
5  These indexes track the actual expenditures associated with an episode of care, 
without holding fixed the service mix.  For example, if chronic episodes of depression are 
now treated with drug therapy, rather than the more costly talk therapy,  the alternative 
index takes into account any cost reductions associated with this switch when quantifying 
what has happened to the cost of treating depression.  We call these “medical care 
expenditure indexes” (MCEs) to emphasize that they track the overall cost of care for a 
condition (all expenditures), not the costs of the individual services.  
                                                           
4 See, for example, Schultze and Mackie (2002) and National Research Council (2010).    
5 See Berndt et al. (2000) and Schultze and Mackie (2002) for a full discussion of the issues.   
  4Below we describe these indexes in detail.  We also discuss a major stumbling 
block to constructing MCE indexes: they require one to measure healthcare spending by 
disease.  Because patients often suffer from more than one illness, or experience 
comorbidities, allocating spending to specific diseases becomes difficult.
6  Because there 
is no consensus on which of the existing allocation methods is best, we do the allocations 
in three ways to explore the robustness of our estimates.   
 
A.  CONSTRUCTING PRICE INDEXES  
 
The conventional indexes currently available, SPIs, separately track expenditures 
for individual services, such as inpatient stays, outpatient visits, or prescriptions.  Official 
price indexes obtain representative bills (e.g. visits to a physician for a particular 
condition) and track prices of similar bills over time.  We mimic this procedure in our 
data by tracking prices for a fixed basket of conditions treated using particular services (a 
bill).     
  The standard formula for an SPI index for service s, SPIs
   that holds the basket of 
conditions and types of encounters in period 2 to that which was provided in period 1 is:   
   
                Σ d cd,s
2 xd,s
1  
    SPIs
       =        --------------   
     Σ d cd,s
1 xd,s
1   
where we denote expenditures for a service used to treat condition d in period 2 using 
service s as cd,s
2 and the associated quantities with xd,s
2. 
Holding the market basket fixed requires holding the x’s at period 1 levels.  The 
numerator indicates how much the services provided to patients treated in period 1 would 
have cost at period 2 prices.   
                                                           
6 A similar issue arises elsewhere in the national accounts when revenues for establishments are allocated to 
industry classes. In this case, the revenues for individual establishments are assigned to an industry 
according to their primary economic activity. Thus, if a business produces goods that fall under two or 
more industries, the business is classified according to its major output.according to their primary economic 
activity. Thus, if a business produces goods that fall under two or more industries, the business is classified 
according to its major output. 
  5In contrast, the preferred MCE index begins by considering the cost of treating 
individual diseases.  Operationally, that cost is calculated by totaling dollars spent on all 
services to treat the condition (e.g. office visit and antibiotics for ear infections) and 
dividing those dollars by the number of cases treated, Nd:  Σscd,s
2 xd,s
2 / Nd
2.  The ratio of 
this price in period 2 to that of period 1 gives disease d’s component for an overall MCE 
and tracks changes in what is spent to treat disease d:  
   
   Σ s (cd,s
2 xd,s
2 ) / Nd
2  
     MCEd
      =     ------------------------ 
    Σ s (cd,s
1 xd,s
1 ) / Nd
1 
    
One can define aggregate versions of the SPI and MCE indexes and compare 
them.  An aggregate SPI for all services that is similar to the BLS indexes takes a 
weighted average of the price indexes for each service using Laspeyres expenditure 
weights:  SPI =  Σ s ws
1 SPIs, where ws
1 = Σ d (cd,s
1 xd,s
1 ) / Σs Σ d (cd,s
1 xd,s
1 ).  Similarly, an 
aggregate MCE aggregates over diseases and conditions using Laspeyres expenditure 
weights.  For example, an overall MCE takes averages of the MCEs for individual 
conditions using wd
1 = Σ s (cd,s
1 xd,s
1 ) / Σ s Σ d (cd,s
1 xd,s
1 ), so that the overall MCE is:  
MCE=  Σ d wd
1 MCEd. 
  As discussed in the literature, differences in the aggregate MCE and SPI indexes 
arise from the fact that the SPI holds the market basket fixed whereas the MCE index 
does not.  Aizcorbe and Nestoriak (2010) derive an expression showing that differences 
in the aggregate MCE and SPI as defined above result from changes in utilization rates 




1):   
 
MCE = SPI + Σ d wd
1 Σ s { SPId,s ( dUd,s – 1) }  
 
where SPId,s =  cd,s
1 xd,s




1 ) , the contribution of disease d to SPIs.   
  Intuitively, this formula says that changes in utilization rates create a wedge 
between the overall SPI and MCE indexes.  For example, with no changes in utilization, 
dUd,s = 0 for all diseases and services, the second term equals zero and the two indexes 
  6coincide (MCE=SPI).  If, instead, there were increases in the utilization of all services, all 
the dU terms would be greater than one and the MCE would show faster price growth—
the overall cost of treating diseases would be increasing faster than the cost of the 
underlying services.   
  The data requirements for constructing MCE indexes are substantially greater 
than those for constructing SPIs.
7  Because SPIs are specific to a type of service (or 
industry), it is possible to collect these data from the usual sources for official statistics:  
hospitals, pharmacies, and other establishments.  Moreover, all one needs is expenditures 
and number of visits or encounters.  In contrast, the MCE indexes require data that allow 
one to add up all the spending associated with the care of a patient, or data that can link 
services to patients.  If such data were available at monthly frequencies, the BLS could 
construct a monthly MCE.  However, the patient-level data typically only allow one to 
construct annual indexes and, so, cannot be used to generate official price indexes in real 
time.   
Given these data constraints, Bradley et al. (2010) use the MEPS survey to study 
potential adjustments to the official Consumer Price Indexes (CPI).  Below, we use the 
MEPS data to assess the usefulness of this strategy by comparing an adjusted SPI to the 
unadjusted SPI and MCE indexes.   
  The proposed index, SPIs
ADJ may be constructed as follows:  for each service, 
construct a weighted average of changes in utilization rates and apply the result to the SPI 
index for that service.  Formally, SPIs




       =      SPIs   Σ d  { (cd,s
1 xd,s
1 / Σ d cd,s
1 xd,s
1} {  dUd,s } 
 
and the aggregate is SPI
ADJ  =  Σ s ws
1SPIs
ADJ, where ws
1= Σ d  cd,s
1 xd,s
1 / (Σ s Σ d cd,s
1 xd,s
1).   
                                                           
7 Currently, BLS conducts several surveys to collect the necessary data to construct its medical price 
indexes. None of these household or outlet surveys collect any information on disease conditions. 
Therefore, it is not possible with current BLS surveys to construct MCE indexes. Changing each of these 
surveys would be prohibitively expensive.  Absent data on each of the components of the MCE indexes, 
approximating an MCE would require i) the use of MEPS to obtain the utilizations, xd,d, and ii) the 
imputation of cd,s
2 /cd,s
1., as discussed below.   
  7To see how this compares with the service indexes implicit in the MCE indexes, 
consider the components of the MCE indexes for services (rather than conditions).  For a 
given service, s, this term may be written,    
 
MCEs
        =        Σ d  { (cd,s
1 xd,s
1 / Σ d cd,s
1 xd,s




This expression says that an MCE index for service s is an expenditure-weighted average 
(1
st term) of the price relative (last term) multiplied by changes in utilization (middle 
term).  This is the ideal index that the BLS should approximate. 
  When comparing the SPIs
ADJ and the MCEs , the SPIs
ADJ is the MCEs with {cd,s
2 / 
cd,s
1}imputed with SPIs .Identifying the assumptions necessary to justify this imputation 
is useful in understanding any differences we find in the SPIs
ADJ and MCE indexes in our 
empirical work.  There are two assumptions that could be applied to this MCEs to obtain 
the SPIs
ADJ.  First, one could assume that the price relatives in MCEs move according to 
the economy-wide SPIs that average over all conditions.  In that case, we would replace 
{cd,s
2/ cd,s
1 } with SPIs and obtain the SPIs
ADJ directly.  This assumption is unrealistic, 
however.  As one example, drug prices show different growth rates depending on the 
entry of new drugs and generics so prices in segments with rapid product introductions 
(like psychotropic medications in recent decades) will likely show very different pricing 
patterns than those in segments with relatively slow innovation.   
  Alternatively, a sufficient condition for MCEs = SPIs
ADJ is that {dUd,s } and { cd,s
2 / 
cd,s
1 } be independent in a particular sense.  To see this, rewrite SPIs
ADJ with SPIs written 
in terms of the underlying cost and utilization data:   
 
SPIs
ADJ = {Σ d (cd,s
1 xd,s




1)} {Σ d ( (cd,s
1 xd,s




This is a product of weighted averages whereas the aggregate MCE is a weighted average 
of products.   
  To find a condition that equates SPIs
ADJ = MCEs
  in expectation, let Ê( ) denote the 
expectations operator under the frequency weight (cd,s
1 xd,s
1 / Σ d cd,s
1 xd,s
1) .  Then, 
SPIs
ADJ will equal MCEs in expectation if:       
  8 
Ê(cd,s
2 / cd,s
1) Ê( dUd,s) = Ê (cd,s
2 / cd,s
1 x dUd,s) for all s.   
 
A sufficient condition is that the (cd,s
2 / cd,s
1) and dUd,s are independent with respect to the 
frequency distribution for all s.  This is satisfied if changes in utilization, dUd,s, are not 
based on the ratio of cd,s
2/cd,s
1.  For example if s is inpatient hospital services and the 
disease is Acute Myocardial Infraction (AMI) then the changes to hospital utilizations 
can not be based on the hospital price ratio for AMI and vice versa.   
In our empirical work, we obtain growth rates using this adjusted SPI and 
compare them to the growth rates of the MCE index to assess how well the adjusted SPI 
approximates the MCE indexes.  We evaluate the differences between the price indexes 
by calculating bootstrapped confidence intervals using the percentile method.    
 
B.  ALLOCATING SPENDING BY DISEASE  
 
  As seen above, the building blocks for these indexes are expenditures and 
utilization for the various services, further broken down by disease.  There are three 
existing methods to allocate expenditures by disease; in our empirical work, we compare 
price indexes constructed with each of the three methods to assess the sensitivity of the 
indexes to how one allocates spending.      
Many studies that attempt to measure expenditures on healthcare by disease have 
traditionally used the concept of “primary diagnosis” to assign spending to disease 
categories.  More recently, these allocations have been tried using proportional methods 
and episode grouping algorithms (known as “groupers”).  While there is no consensus 
about which of these alternative methods is best, work by Cutler and Rosen (2007) is 
underway to assess the relative merits of these methods for different purposes.     
 
1.  PRIMARY DIAGNOSIS METHOD 
 
The simplest method allocates all spending from a medical encounter to the first-
listed diagnosis on an insurance claim, which is assumed to be the “primary diagnosis.”  
  9The primary diagnosis is considered the condition that prompted the encounter with the 
healthcare system, resulting in the spending being allocated entirely to that disease. Of 
course, this method does not account for the contribution of comorbidities to 
expenditures.  The nature and magnitude of this omission, as well as the specific 
diagnoses affected, remain unknown (Cohen 2002). 
In addition to the precedent set in national accounting practice for other sectors, 
this is the method used in the traditional cost of illness studies to measure spending for 
particular diseases.
8  One advantage to this method moving forward is that the U.S. 
Census Bureau plans to collect data on spending by disease using this method beginning 
with the 2012 Economic Census.  
 
2. PROPORTIONAL ALLOCATION METHOD 
 
  An alternative to the primary diagnosis method is allocating some of the spending 
from a single medical encounter to all of the diagnoses reported for the encounter.  The 
particular amount allocated to each condition is based on encounters where only one 
diagnosis is reported.  As described in Thorpe et al. (2004): 
“We tabulated spending per event for those reporting a single medical condition 
(for example, heart disease and no other condition). We then tabulated spending 
per event for those reporting two or more medical conditions associated with the 
event (for example, heart disease and hypertension). We calculated the ratio of 
these two spending totals and used it to determine how much of the spending 
associated with heart disease plus other conditions should be attributed to heart 
disease.” 
 
This method was also used recently by Roehrig et al. (2009) to form time series of 
spending on 18 disease groups and by Bradley et al. (2010) to construct price indexes.     
The advantage of this method over the primary diagnosis method is that it allocates some 
spending to all of the conditions reported with the encounter, thereby beginning to 
address the issue of comorbidities.  The drawback is that it is not clear if spending from 
encounters with only one diagnosis listed is a good way to allocate spending for other 
encounters.   
                                                           
8 Rice (1967) is the seminal study; see Hodgson and Cohen (1999) for more recent work.   
  103.  EPISODE GROUPING ALGORITHMS
9 
 
Unlike the primary diagnosis and proportional approaches, episode grouping 
algorithms use information from patients’ histories—not just from individual 
encounters—to allocate spending to disease groups.  This method has been used to 
construct price indexes by Berndt et al. (2001), Song et al. (2009), Aizcorbe and 
Nestoriak (2010), and Dunn et al. (2010).  The major drawback to this method is that it is 
relatively new and is viewed by many as a black-box because the allocation method is not 
readily transparent. 
Similar to other grouping algorithms, Thomson Reuters’ Medical Episode 
Grouper (MEG) uses all encounters a patient has with the medical care system over a 
period of time to create what is referred to as an episode of care; the information gained 
after the grouping process allows one to assign costs to specific episodes.  The grouping 
process considers each claim to be a single record, using diagnosis information to 
determine assignments of costs to episodes (MaCurdy et al. 2008).   
Each episode is classified as chronic, acute, or preventative.  The latter two 
classifications typically have clearly defined start and end dates, whereas chronic 
episodes have a user-defined episode length, usually of one year.  The MEG grouper 
assigns each episode to one of 560 disease categories, and also accounts for the severity 
of a disease (MaCurdy et al. 2008).   
The primary goal of grouping algorithms is constructing episodes of care and 
assigning a unique disease classification to each episode; however we only use the 
disease allocation assigned to each claim in order to count the number of cases treated for 
particular conditions over a given time period (essentially, number of patients). 
  
III.  DATA 
 
The methods described in the previous section are all applied to the Medical 
Expenditure Panel Survey (MEPS) data for the years 2001-2005 in order to create the 
                                                           
9 See MaCurdy et al. (2008), Rosen and Cutler (2009) and National Research Council (2010) for 
  11various types of price indexes.  We focus on this period in part because the earlier years 
(1998-1999) of the MEPS survey contain substantially fewer observations;  furthermore, 
the recommended application of the MEG episode grouper calls for dropping the first and 
last years of the sample (2000 and 2006).     
MEPS, which is conducted by the Department of Health and Human Services’ 
Agency for Healthcare Research and Quality (AHRQ) is a survey of the healthcare 
utilization and expenditures that may be used to obtain nationally representative estimates 
for the civilian non-institutionalized U.S. population.  As a data source, MEPS is a well-
known, nationally representative sample, and is generally regarded as a high quality 
source of data on high-prevalence health conditions.  Another important strength of the 
MEPS data is its ability to directly link expenditures from all services (across all types of 
providers) to patient care events (Mackie 2009; Sing et al. 2006).  Finally, MEPS is the 
only data set available to capture the expenditures of the uninsured (Cohen 2009).   
The main drawback to these data stems from its small sample size.  Although 
15,000 families (35,000 individuals) are surveyed per year (Cohen, Cohen, and Banthin 
2009), it has been shown that the MEPS survey undercounts spending for many 
conditions and misses high-cost cases (Aizcorbe et al. 2010).
10  Depending on how many 
disease groups one wants to consider, this could lead to very few observations for many 
of the cells that we use as building blocks for our indexes.
11   
With regard to variables, the MEPS survey provides both household- and patient-
level data on personal healthcare expenditures.  The survey contains data on health 
services used as well as the frequency with which households use them, their cost, and 
how they are paid for.
12  An observation in the data corresponds to a medical encounter.  
                                                                                                                                                                             
discussions and perspectives on the usefulness of these episode grouping algorithms.    
10 The survey sample is drawn from the prior year’s National Health Interview Survey (NHIS) sampling 
frame.  The survey uses an overlapping panel design in which the data are collected through a series of five 
rounds of interviews; the data from the overlapping panels are then used to produce annual estimates.  For 
each household surveyed, MEPS interviews a single respondent – the family member most knowledgeable 
about the entire household’s health and healthcare use (Zuvekas and Olin 2009a).  . 
11 Despite these disadvantages, we find MEPS to be a suitable dataset for adjusting the SPI.  While claims 
data has superior information on prices, these data are expensive to obtain and there is a risk of the vendor 
failing to supply the data at any given time. 
12 MEPS actually consists of a family of three interrelated surveys:  the Household Component (HC), the 
Medical Provider Component (MPC), and the Insurance Component (IC). The Household Component of 
the survey interviews individuals and families; the Medical Provider Component supplements this 
information by verifying prices, but not quantities, from medical providers and pharmacies.  The final 
  12For each encounter, the public use file provides up to four diagnoses, the type of service 
(inpatient confinement, outpatient care, either at outpatient hospitals or physician offices, 
or pharmacies), and the expenditure; expenditures are measured as the amount received 
by all providers of the services (including both out-of-pocket payments and amounts paid 
by insurance firms).  
We use events from the following files:  inpatient confinements, outpatient 
hospital care, office visits, emergency room care, and prescription drugs.  We sum the 
number of encounters assigned to a each condition to obtain the number of encounters, 
designated with an “x” as discussed above. We measure the number of cases treated for 
disease d as the number of patients that received treatment for a disease d in a given 
period. 
In the MEPS data, the overwhelming majority of events only contain one 
diagnosis (84 percent).  The fact that very few comorbidities are reported and that the 
three methods rely so heavily on primary diagnoses means these data may not yield 
significant differences between the price indexes calculated from the three methods.   
Processing the data with the MEG grouper requires 5-digit ICD-9 codes on 
medical records, valid NDC codes for prescription drugs, and valid dates for each event.  
For medical events, the MEPS public-use file only reports 3-digit ICD-9 codes , which 
the MEG grouper cannot process.  We obtained the 5-digit codes from AHRQ and 
merged them with the event files.  For drug events, about half of the NDC codes 
associated with drug events were not valid and could not be assigned a disease category 
by the MEG grouper; however, because drug events in MEPS have self-reported ICD-9 
codes, the other methods are able to allocate the spending.  With regard to dates, when 
there was a response for the month of service but no specific date, we arbitrarily assigned 
the event to the first day of the reported month.  For drug events, the month of service 
was often missing.  In those cases, we assigned those drug records to December 31 of the 
year in which they appeared.  Although this does not affect how these records are 
assigned to disease classes (the MEG grouper does not use timing of services to assign 
                                                                                                                                                                             
component is the Insurance Component, which collects data from employers regarding the employers’ 
characteristics and the insurance they offer their employees (Sing et al.2006; Zuvekas and Olin 2009b; and 
Cohen, Cohen, and Banthin 2009). 
  13drug events to disease classes), this means we can only produce indexes with an annual 
frequency.
13   
The resulting data provide the building blocks for constructing the 
aforementioned indexes.  An important practical issue is ensuring that the data are 
sufficiently rich to support these calculations.  The MCE indexes require measures for 
each disease in each period and one needs to ensure that these cells are sufficiently 
populated to support precise estimates of price growth.  For example, the MEG grouper 
uses 560 disease categories.  If patients were distributed uniformly across disease classes, 
this would place about 60 of the 30,000 or so patients each year into each disease cell.   
However, patients are not distributed uniformly and this leads to thin cells with 
too few observations to support valid price indexes.  As seen in Table 1,using the 560 
MEG disease categories, only 413 of them are populated at all (we do not observe any 
patients for the rest) and among those, the median number of observations is 15, with 25 
percent of the cells containing three or fewer observations.   
It is possible to aggregate over these disease classes to categories that are coarser 
and, hence, will contain more observations.  The Summary Diagnostic Category (SDC) 
schema folds the 560 MEG disease groups into 195 disease groups; the Medical 
Diagnostic Category (MDC) further groups these into 23 classes.  Similarly, ICD-9-based 
groupings—like those from the primary and proportional approaches—can be scrolled up 
to the Clinical Classification System (CCS) level or the CCS chapter level.   
The obvious tradeoff is that coarser disease groups have patients with less 
homogeneous conditions.  In our empirical work, we construct MEG indexes at the SDC 
level and the primary and proportional methods at the 200+ CCS level.  For ease of 
reporting, we take weighted averages of these disaggregate indexes to report them at the 
chapter level or overall.   
 
IV.  STUDY FINDINGS 
 
For each of the three allocation methods, we construct measures of spending by 
disease and the corresponding implied price indexes.  We then consider the adjusted SPI 
                                                           
13 If BLS applied these methods to their CPI and PPI data, they would be able to produce monthly indexes. 
  14method and assess how well it approximates the MCE indexes.  All estimates are 
nationally representative in that all indexes are based on data weighted by the sampling 
weights provided in the MEPS data.   
  
A.  SPENDING BY DISEASE 
 
  We compared how the three methods allocated spending to disease categories in a 
number of ways.  First, the primary and proportional methods are easy to compare 
because they are on the same disease schema (ICD-9, CCS, and chapters).  At the CCS 
level, the allocations by these two methods are very similar— a correlation coefficient 
over the 200 or so disease classes is .9.  We attribute this similarity to the fact that the 
only difference in the allocations for these two methods would come from the presence of 
more than one diagnosis on each record and that happens only rarely in the MEPS data 
(18 percent of records).   
  At the CCS level, we assess the similarity between the MEG allocations to the 
primary method by assessing how well each of the MEG classes maps into a CCS class.  
We do this according to the CCS where most of that MEG’s spending is allocated.  If the 
allocations are identical, each MEG would map into only one CCS class.  In our data, we 
find that the allocations are very similar in that about half of the MEG disease groups 
map over 90 percent of their spending into one CCS class.  We attribute this similarity to 
the fact that both methods rely heavily on the primary diagnosis to allocate spending.  
However, there are differences:  the other half of the disease groups contain spending that 
the episode grouper algorithm assigns to many different CCS classes.  This is evidence 
that the MEG and algorithm methods do in fact allocate spending differently.   
  We also compare the allocations at the broader CCS chapter level by mapping 
each MEG directly to the chapters, rather than the CCS classes.  The mapping at the 
chapter level is much more precise, with 90 percent of the MEG disease classes 
allocating at least 82 percent of spending to one CCS category.  To compare spending at 
the chapter level, we assign each MEG to the CCS class where most of the spending 
goes.   
  15  The left panel of Table 2 shows how the three methods allocate spending into 
CCS chapters.  As seen at the bottom, MEG does not allocate about 10 percent of 
spending to disease categories; these are virtually all drug claims.  About one-half of the 
unallocated spending happens when the NDC codes that MEG uses are invalid; the rest is 
spending that MEG cannot allocate because it is for patients that have no episodes of care 
in the data to which MEG can associate the drug spending (called orphan records).
14  In 
contrast, the primary and proportional approaches use ICD-9 codes to allocate spending 
and use the self-reported diagnosis codes on the drug claims to allocate drug spending to 
diseases.   
 Excluding drug events, the spending allocations by the three methods to CCS 
chapters are much more similar (see right panel of Table 2).  For example, in the case of 
mental illness—a group with substantial drug spending—the three methods have very 
similar allocations once drug spending is excluded but the spending allocated by MEG is 
25 percent less than the other two methods when drug spending is included.   
These differences in the spending levels attributed to diseases may or may not 
translate into differences in price indexes.   
 
B. PRICE INDEXES 
 
We construct an SPI index based on the MEG allocation of spending and compare 
that index to three MCEs constructed using the three allocation methods:  principal 
diagnosis, proportional, and MEG.  To explore how sensitive price indexes are to the 
underlying allocation of spending, we calculate price indexes based on each of these 
methods and compare them.   
The resulting indexes—averaged over all diseases—are shown in Figure 1.  The 
overall SPI index is the solid line while the three MCE indexes are the dashed lines. The 
difference between each of the MCEs and the SPI represents an estimate of the bias 
present in the official prices. 
                                                           
14 One could fool MEG by processing the drug events as if they were ancillary services, in which case 
MEG would use the ICD-9 code to allocate the spending.  This would take care of those claims that had 
invalid NDC codes but would not take care of the orphan records.   
  16  Over the period 2001-2005, all indexes show rapid price growth but the SPI index 
is consistently higher than the other three indexes, growing faster than the MCE indexes 
in three of the four years. The average compound annual growth rates are 7.8 percentage 
points for the SPI index and 6.9, 6.6, and 6.8 percentage points for the principal 
diagnosis, proportional, and MEG indexes, respectively.  The estimated bias is, therefore, 
around one percentage point per year, depending on the spending allocation method.  
This estimate of the bias is lower than that reported in Aizcorbe and Nestoriak (2010) but 
higher than that in Dunn et al. (2010) and Bradley et al. (2010).     
  That the three MCE indexes show very similar rates of growth reflects how 
similar the spending allocations are in the MEPS data, where the vast majority of MEPS 
event records have only one reported ICD-9 code.  This result, therefore, may not hold up 
in datasets that report more than one diagnosis on event records.  Moreover, the exclusion 
of drug spending from the MEG index does not appear to generate substantial differences 
in the MCE indexes.   
  We next construct the adjusted SPI index and compare it to the unadjusted SPI 
and MEG indexes.  As seen in Figure 2, the adjusted SPI is very similar to the MEG 
index:  both grow around 6.8 percent per year, about one percentage point less than the 
unadjusted SPI.  At first blush, SPIADJ does a reasonable job of approximating a disease-
based index.
15 
    
V.  CONCLUSION 
 
This study uses MEPS data to determine i) the effect on published health inflation 
data if the price index were to change from a service price index (SPI) to an alternative 
index that accounts for changes in service mix when treating a disease (MCE), ii) the 
difference between using the adjustment method used in Bradley et al and the MCE 
indexes, iii) and how using different disease classifications and comorbidity methods 
impact the MCE indexes. 
                                                           
15 One caveat to our results lies in the precision of the estimates.  We constructed bootstrapped confidence 
intervals for the SPIADJ and MCE indexes and could not reject the null that the growth in these indexes 
was the same as that in the SPI index.  This underscores the importance of finding ways to combine the 
  17Comparing SPI and MCE indexes, this study finds that traditional price index 
methods generate an annual 1 percentage point upward bias on the medical price indexes 
that are computed with traditional methods.  This translates into an overall .2 percentage 
point overstatement for overall inflation with an attendant understatement of the same 
amount to GDP growth, per year.  This is a substantial bias that is consistent with results 
found in earlier studies.  The results also suggest that one can approximate the MCE 
indexes using the method studied in Bradley et al; the resulting SPIADJ grows at rates 
comparable to the MCE indexes.  Finally, these results are robust to how one allocates 
spending by disease; the three alternative methods considered yield very similar growth 
rates.   
  More work is needed to explore the robustness of this result to choice of dataset 
and methods.  With regard to the data, it would be useful to confirm that this result holds 
up in other datasets where more diagnoses are reported.  With regard to the MCE indexes 
that we use as our benchmark, it would be useful to see how they compare to indexes 
constructed using other methods for allocating cost by disease, particularly the methods 
currently under development by Cutler and Rosen.   
 
  
                                                                                                                                                                             
richness of claims data with representative surveys like the MEPS in order to improve the precision of these 
indexes.      
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 Table 1. Cell Counts for MCE and SPI Indexes
MEG Episode Grouper
MEG SDC MDC CCS Chapter CCS Chapter
Number of Possible Disease Classes 560 195 23 249 18 249 18
Number Populated with Data 413 191 23 234 18 235 18
Within Populated Cells
    Median Number of Patients 15 60 1814 66 3165 71 3250
    IQR 3-80 16-190 319-2156 16-264 1354-4951 18-295 1346-5155
    Median Number of Services 14 30 367 28 569 29 577
    IQR 3-64 8-129 98-1619 6-124 137-3018 6-137 154-3133
Primary Diagnosis Proportional ApproachTable 2. Alternative Allocations of Spending By Disease, 2005
EA PA MEG EA PA MEG
1 Infectious and parasitic diseases 12,125 $     12,658 $     10,443 $     7,202 $       7,801 $       6,886 $      
2 Neoplasms 70,811 $     71,336 $     72,506 $     67,414 $     67,924 $     70,965 $    
3 Endocrine; nutritional; and metabol 59,270 $     58,982 $     41,848 $     19,631 $     19,422 $     19,574 $    
4 Diseases of the blood and blood-for 9,675 $       10,060 $     4,048 $       3,924 $       4,288 $       3,941 $      
5 Mental Illness 46,608 $     46,480 $     35,621 $     23,051 $     22,853 $     23,714 $    
6 Diseases of the nervous system and 52,570 $     51,273 $     45,724 $     41,343 $     40,125 $     37,281 $    
7 Diseases of the circulatory system 120,894 $   121,774 $   120,238 $   88,462 $     89,270 $     96,081 $    
8 Diseases of the respiratory system 61,666 $     60,526 $     53,660 $     41,132 $     40,062 $     41,983 $    
9 Diseases of the digestive system 63,723 $     64,161 $     51,972 $     48,570 $     48,976 $     46,544 $    
10 Diseases of the genitourinary syste 51,472 $     51,863 $     52,131 $     44,525 $     44,990 $     43,939 $    
11 Complications of pregnancy; childbi 34,110 $     34,302 $     35,569 $     32,254 $     32,421 $     35,057 $    
12 Diseases of the skin and subcutaneo 16,587 $     14,693 $     14,306 $     13,565 $     11,659 $     12,790 $    
13 Diseases of the musculoskeletal sys 73,121 $     73,584 $     68,471 $     57,741 $     58,194 $     57,197 $    
14 Congenital anomalies 5,411 $       5,624 $       5,265 $       5,121 $       5,346 $       5,086 $      
15 Certain conditions originating in t 1,823 $       1,907 $       1,830 $       1,823 $       1,907 $       1,823 $      
16 Injury and poisoning 68,577 $     69,796 $     69,701 $     66,982 $     68,203 $     67,515 $    
17 Symptoms; signs; and ill-defined co 21,741 $     21,191 $     8,807 $       10,940 $     10,399 $     5,959 $      
18 Residual codes; unclassified; all E 8,944 $       8,919 $       2,119 $       4,666 $       4,508 $       1,731 $      
Unallocated - $              - $              84,876 $     - $              - $              280 $        
779,130 $   779,130 $   779,135 $   578,346 $   578,346 $   578,346 $  
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